Companies › TuHURA Biosciences
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IFx-Hu2.0 Innate immune agonist | – | Phase 2 | Advanced Or Metastatic Merkel Cell Carcinoma | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06947928 | IFx-Hu2.0 | Phase 2 | Advanced Or Metastatic Merkel Cell Carcinoma | Oncology | Mar 2027 |
| NCT06940440 | IFx-Hu2.0 | Phase 1 | Advanced Or Metastatic Merkel Cell Carcinoma | Oncology | Apr 2027 |
Cash of $1m on 2026-06-30; operating cash outflow about $26m a year; runway about 0 months at that burn, to Jul 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
No annotated target.
–
Oncolytics Biotech Cardiff Oncology Actuate Therapeutics Inhibrx Biosciences Genelux
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.